Healthcare provider profile · identity verified

Kafi Rudolph, D.O.

Family Practice · CHERRY HILL, NJ · NPI 1023499340

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	495	184
Amlodipine Besylate	Amlodipine Besylate	291	105
Levothyroxine Sodium	Levothyroxine Sodium	175	65
Metformin Hcl	Metformin Hcl	151	58
Lisinopril	Lisinopril	145	52
Rosuvastatin Calcium	Rosuvastatin Calcium	126	47
Losartan Potassium	Losartan Potassium	121	49
Albuterol Sulfate Hfa	Albuterol Sulfate	120	35
Hydrochlorothiazide	Hydrochlorothiazide	109	39
Gabapentin	Gabapentin	107	33
Famotidine	Famotidine	102	39
Metoprolol Succinate	Metoprolol Succinate	102	35
Omeprazole	Omeprazole	96	37
Montelukast Sodium	Montelukast Sodium	84	24
Pantoprazole Sodium	Pantoprazole Sodium	82	39
Fluticasone Propionate	Fluticasone Propionate	77	29
Trazodone Hcl	Trazodone Hcl	65	18
Ezetimibe	Ezetimibe	62	24
Allopurinol	Allopurinol	59	18
Pravastatin Sodium	Pravastatin Sodium	58	23
Carvedilol	Carvedilol	52	21
Valsartan	Valsartan	51	17
Hydralazine Hcl	Hydralazine Hcl	50	21
Furosemide	Furosemide	49	22
Sertraline Hcl	Sertraline Hcl	49	18
Glimepiride	Glimepiride	44	18
Metoprolol Tartrate	Metoprolol Tartrate	44	17
Tamsulosin Hcl	Tamsulosin Hcl	42	17
Escitalopram Oxalate	Escitalopram Oxalate	37	12
Buspirone Hcl	Buspirone Hcl	36	suppressed
Metformin Hcl Er	Metformin Hcl	35	13
Zolpidem Tartrate	Zolpidem Tartrate	35	12
Ibuprofen	Ibuprofen	34	suppressed
Alendronate Sodium	Alendronate Sodium	33	11
Clopidogrel	Clopidogrel Bisulfate	32	11
Lorazepam	Lorazepam	32	15
Alprazolam	Alprazolam	31	suppressed
Eliquis	Apixaban	29	11
Jardiance	Empagliflozin	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	28
Olmesartan Medoxomil	Olmesartan Medoxomil	28	suppressed
Baclofen	Baclofen	27	suppressed
Farxiga	Dapagliflozin Propanediol	27	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	22	19
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Simvastatin	Simvastatin	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Ozempic	Semaglutide	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Clonazepam	Clonazepam	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Meloxicam	Meloxicam	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Cephalexin	Cephalexin	16	12
Incruse Ellipta	Umeclidinium Bromide	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Prednisone	Prednisone	16	13
Synthroid	Levothyroxine Sodium	16	suppressed
Naproxen	Naproxen	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Diazepam	Diazepam	14	suppressed
Ramipril	Ramipril	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Finasteride	Finasteride	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Risperidone	Risperidone	11	suppressed
Sildenafil Citrate	Sildenafil Citrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error